Cheryl Cho-Phan
Clinical Trials
- Recruiting ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
- Not Recruiting Combination SBRT (Stereotactic Body Radiotherapy) With TACE (Transarterial Chemoembolization) for Unresectable Hepatocellular Carcinoma
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
- Not Recruiting Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
- Not Recruiting Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
- Recruiting A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
- Recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Not Recruiting Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
- Not Recruiting Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
- Not Recruiting Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
- Not Recruiting A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
- Recruiting HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Help
Trial Administration